Principal Investigator: Dr. Aileen Chang​
Disease: Dengue Fever
Research Description: Dengue viruses (DenV) are among the leading causes of pediatric morbidity and mortality globally, with 96 million symptomatic cases annually worldwide and no targeted treatments. Once infected by DenV, individuals who are symptomatic often experience high fever, muscle and joint pain, and rash. However, some individuals can develop more severe symptoms leading to dengue shock syndrome. Low and lower-middle income countries suffer from DenV infections disproportionately, due to lack of healthcare infrastructure and capacity to manage dengue cases.
Repurposing a Flu Treatment for Severe Dengue Patients in Colombia
Latest News
Aileen Chang and other experts discuss the Chikungunya Virus in this CME roundtable:
Chikungunya Virus: Climate Change, Disease Spread, and the Need for Prevention
We are thrilled to announce that The Chang Lab is currently enrolling participants for our groundbreaking clinical trials being conducted in Barranquilla, Colombia! This marks a significant step forward in our translational research efforts.
In 2020, Cures Within Reach funded Dr. Aileen Chang at George Washington University to support a Phase I trial evaluating the safety and efficacy of an approved flu drug, zanamivir, for patients with severe dengue infections in Colombia.